ZIOPHARM Oncology Inc (NASDAQ:ZIOP) is scheduled to be issuing its quarterly earnings data after the market closes on Monday, July 31st. Analysts expect the company to announce earnings of ($0.13) per share for the quarter.

ZIOPHARM Oncology (NASDAQ:ZIOP) last announced its quarterly earnings results on Monday, May 1st. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by $0.03. The business had revenue of $1.60 million during the quarter, compared to the consensus estimate of $1.71 million. The firm’s quarterly revenue was down 18.8% compared to the same quarter last year. On average, analysts expect ZIOPHARM Oncology to post $-0.58 EPS for the current fiscal year and $-0.64 EPS for the next fiscal year.

Shares of ZIOPHARM Oncology Inc (NASDAQ ZIOP) traded down 5.20% during midday trading on Thursday, hitting $5.65. The company’s stock had a trading volume of 1,321,354 shares. The company’s market cap is $738.46 million. The company has a 50-day moving average price of $5.92 and a 200 day moving average price of $6.35. ZIOPHARM Oncology Inc has a 1-year low of $4.55 and a 1-year high of $7.88.

A number of research analysts have recently issued reports on the company. ValuEngine raised ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research note on Monday, July 17th. HC Wainwright assumed coverage on ZIOPHARM Oncology in a research note on Thursday, June 1st. They issued a “buy” rating and a $9.50 price objective on the stock. Finally, Zacks Investment Research raised ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research note on Wednesday, April 26th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $13.00.

COPYRIGHT VIOLATION NOTICE: This news story was first posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of United States and international copyright laws. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/07/27/ziopharm-oncology-inc-nasdaqziop-scheduled-to-post-quarterly-earnings-on-monday.html.

ZIOPHARM Oncology Company Profile

ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.

Earnings History for ZIOPHARM Oncology (NASDAQ:ZIOP)

Receive News & Ratings for ZIOPHARM Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.